Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 5552

AbstractMaterial and MethodsResultsDiscussionConclusionAcknowledgementReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Original article / research
Year : 2022 | Month : January | Volume : 16 | Issue : 1 | Page : EC11 - EC15 Full Version

Peritumoural and Tumour Infiltrating Lymphocytes in Breast Carcinoma and their Relation with Tumour Grade, Lymphovascular Emboli and Nodal Metastasis: A Cross-sectional Study


Published: January 1, 2022 | DOI: https://doi.org/10.7860/JCDR/2022/51545.15879
Sreeja Jayalakshmi, Anupama Achyuthan Manjula

1. Senior Resident, Department of Pathology, Government Medical College, Kozhikode, Kerala, India. 2. Additional Professor, Department of Pathology, Government Medical College, Manjeri, Malappuram, Kerala, India.

Correspondence Address :
Anupama Achyuthan Manjula,
Additional Professor, Department of Pathology, Government Medical College,
Manjeri, Malappuram, Kerala, India.
E-mail: anupamapathology@gmail.com

Abstract

Introduction: Inflammatory cell infiltrate in tumours may be involved in immunosurveillance or tumourigenesis. Tumour Infiltrating Lymphocytes (TILs; within the tumour) and peritumoural lymphocytes (at the invasive margin) are associated with improved prognosis and response to therapy.

Aim: To estimate the presence of peritumoural lymphocytes and TILs in breast carcinoma, identify their subsets by Immunohistochemistry (IHC) and assess the relationship between them and tumour grade, lymphovascular emboli and axillary lymph node metastasis.

Materials and Methods: This was a cross-sectional study with a sample size of 75 done in the Department of Pathology, Government Medical College, Kozhikode, Kerala, India from November 2017 to April 2019 with the approval of Institutional Ethics Committee. The demographic data of the patients were collected and histopathological assessment of tumour type, grade, lymphovascular emboli, nodal metastasis and lymphocytic infiltrate was done on Haematoxylin and Eosin (H&E) stained sections. Immunohistochemical evaluation was performed using antibodies against Cluster of Differentiation 4 (CD4) and CD8 and cells were scored separately in the stromal and peritumoural areas. The results were analysed by Analysis of Variance (ANOVA) and Chi-square test. Association between the immune infiltrate and histopathological variables were assessed separately in stromal and peritumoural compartments. Association between the score obtained on H&E and subpopulation score obtained on IHC was also analysed in both the compartments.

Results: Total of 75 subjects were included and the mean age was 52.31 years with a standard deviation of 9.774 years. The degree of stromal TIL infiltrate ranged from 10% to 95%, with a mean of 48.47%. High grade peritumoural infiltrate was seen in 66.67% (50 out of 75 cases). The stromal TILs were significantly higher in higher grade tumours and tumours without nodal metastasis. The peritumoural lymphocytes were also significantly higher in high grade tumours. The scoring of the immune infiltrate on H&E sections and subpopulation score on IHC showed significant association for both stromal and peritumoural compartments.

Conclusion: Stromal TILs and peritumoural lymphocytes were significantly higher in high grade tumours. Stromal TILs were also significantly higher in tumours without axillary lymph node metastasis. No significant association was found between the lymphocytic infiltrate and lymphovascular emboli. The immune infiltrate within breast carcinoma has association with tumour grade and lymph node metastasis.

Keywords

Breast cancer, Immune infiltrate, Immunohistochemistry, Prognostic value

Invasive Breast Carcinoma (IBC) is the most common malignancy in women, accounting for nearly 25% of all malignancies in women (1),(2). The incidence of IBC in India is approximately 25.8 per 100,000 women (3). Inflammatory cell infiltrate in tumours, referred to as TILs may be involved in immunosurveillance or tumourigenesis. Immunosurveillance is the mechanism by which the host immune effector cells actively search for and eliminate preneoplastic cell clones. Disease progression occurs when the tumour cells eventually escape from the immune control. This dual host protective and protumourigenic roles of the immune system is known as cancer immunoediting (4).

TILs are of two types based on their relationship to the tumour cell nests; intratumoural TILs lie within the cell nests and have cell-to-cell contact with the tumour cells without any intervening stroma, whereas stromal TILs lie in the stroma between the tumour cell nests without any direct contact with the tumour cells. The evaluation of intratumoural TILs in addition to stromal TILs is currently not recommended (5). TILs are associated with a good prognosis in various malignancies, with improved relapse free and overall survival. The TIL density also shows correlation with tumour depth and Lymphovascular Invasion (LVI) (6). Peritumoural lymphocytes are the immune infiltrate present at the invasive margin of the tumour. Similar to TILs, they have prognostic and predictive significance, with higher number of peritumoural lymphocytes at the invasive margin of melanoma metastasis correlating with improved response to immune checkpoint inhibition (7).

The immune infiltrate within tumours is heterogeneous. Various studies have shown that CD8+ cytotoxic T lymphocytes are the principal cells involved in tumour immunity, along with Type 1 T helper (Th1) CD4+ T lymphocytes, M1 macrophages, natural killer cells, Th17 CD4+ T cells and dendritic cells; whereas Th2 CD4+ T cells, FOXP3+ (forkhead box P3) regulatory T cells, M2 macrophages, neutrophils and B lymphocytes are likely involved in tumour progression (8),(9).

TILs in breast cancer are associated with improved prognosis and response to therapy (5),(10). Relatively fewer studies have been reported from India in this regard. Hence, present study was conducted with the aim to estimate the density of peritumoural and stromal tumour infiltrating lymphocytic infiltrate in breast carcinoma, identify and score their subsets by IHC and assess the relationship between them and the tumour grade, presence of lymphovascular emboli and axillary lymph node metastasis.

Material and Methods

This cross-sectional study was conducted in the Department of Pathology, Government Medical College, Kozhikode, Kerala, India from November 2017 to April 2019. The study was approved by the Institutional Ethics Committee (Ref. No.GMCKKD/RP 2017/IEC/190 dated 15-11-2017). Informed consent was obtained from all patients included in the study.

Sample size calculation: Taking the proportion of cases of breast carcinoma with peritumoural lymphocytes and TILs as 58% (10),

By applying the formula N=4pq/d2

p=prevalence=58 (10),

q=100-p=42

d=precision=20% of p=11.6

Sample size calculated is N=73.

Inclusion criteria: Initial consecutive 75 patients who had undergone mastectomy with proven IBC during the study period were included in the study.

Exclusion criteria: Postchemotherapy and postexcision biopsy mastectomy specimens were excluded from the study.

The clinicopathological parameters evaluated were patient’s age, tumour size, tumour stage, histologic subtype and histologic grade. The tumours were subtyped according to the 2012 World Health Organisation (WHO) classification (1) and graded into grades 1, 2 or 3 as per the modified Bloom and Richardson grading (11), by microscopic examination of H&E stained Formalin Fixed Paraffin Embedded (FFPE) sections. The presence of lymphovascular emboli and axillary nodal metastasis were also assessed. The tumour stage was determined according to the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging criteria (12),(13).

The H&E sections were examined for the presence and density of peritumoural lymphocytes and TILs (stromal TILs). The stromal TILs were quantitatively assessed as per the recommendations of the International TILs Working Group, as percentage of stromal TILs (5).

% Stromal TILs= Area occupied by mononuclear inflammatory infiltrate / Total intratumoural stromal area ×100

The peritumoural lymphocytes were semi-quantitatively scored according to the method adopted by Klintrup K et al., into scores 0, 1, 2 and 3 (14), as given below. The scores 0 and 1 were collapsed into low grade inflammation and scores 2 and 3 into high grade inflammation:

• Score 0=No increase in inflammatory cells.
• Score 1=Mild and patchy increase in inflammatory cells at the invasive margin, but no destruction of invading cancer cell islets by the inflammatory cells.
• Score 2=Inflammatory cells forming a band-like infiltrate at the invasive margin with some destruction of cancer cell islets by inflammatory cells.
• Score 3=Very prominent inflammatory reaction, forming a cup-like zone at the invasive margin, with invariable destruction of cancer cell islets.

Formalin fixed paraffin embedded tissue sections with maximum lymphocytic infiltrate, exclusive of hemorrhagic and necrotic areas, were subjected to manual IHC staining for CD4 (Clone: EP204, Isotype: Rabbit IgG, PathnSitu, Livermore, USA) and CD8 (C8/468, Isotype: Mouse IgG1, PathnSitu, Livermore, USA).

The immunostained slides were examined to identify the individual cell type within the infiltrate. A semi-quantitative measurement of the infiltrate was done under light microscope, independently by two pathologists, based on a modification of the criteria originally proposed by Kreike B et al., as follows (15):

• Absent- No lymphocytes
• Minimal- <10 lymphocytes per high power field (hpf)
• Moderate- Lymphocytes easily identified, but no large aggregates
• Extensive- Large aggregates of lymphocytes in more than 50% of the tumour

The CD4+ cells and CD8+ cells were individually scored into scores 0, 1, 2 and 3 both in the stromal and the peritumoural compartment, corresponding to absent, minimal, moderate and extensive, respectively as per the criteria proposed by Kreike B et al., (15). In immunostaining, only strong membranous positivity was considered positive.

Statistical Analysis

The relationship between the lymphocytic infiltrate and the tumour grade, lymphovascular emboli and axillary nodal metastasis were analysed. Qualitative variables were expressed as frequency and percentage, and quantitative variables as mean and standard deviation. The statistical analysis was done using the Chi-square test, t-test or the ANOVA test depending on the nature of the variable. All the data collected was entered in Microsoft Excel and analysis was done with the help of Statistical Package for the Social Sciences software version 18.0 (SPSS Inc., Chicago, USA). A p-value of <0.05 was considered statistically significant.

Results

The age of the patients studied ranged from 30 years to 82 years, with a mean age of 52.31 years (standard deviation=9.774 years). Majority of the cases 27 (36%) were in the age group of 50 to 59 years. Of the 75 patients studied, 73 (97.33%) were females and two cases (2.67%) were males. 30 (40%) patients had breast carcinoma on the right side and 45 (60%) had it on the left side.

Out of 75 patients, 71 (94.67%) had IBC, Not Otherwise Specified (NOS) and four cases (5.33%) had IBC with medullary features. Of the 71 cases of IBC, NOS, two cases (2.82%) were grade 1, 59 (83.10%) were grade 2 and 10 (14.08%) were grade 3. Seventeen (22.67%) cases showed lymphovascular emboli, and 33 (44%) cases had axillary node metastasis. Of the 33 patients with axillary node metastasis, 17 (51.52%) had one to three positive nodes, 15 (45.45%) had four to nine positive nodes and one case (3.03%) had >10 positive nodes.

In 14 (18.67%) cases, the maximum tumour dimension was <2 cm (T1), 53 (70.67%) cases measured >2 cm to <5 cm (T2) and four cases (5.33%) cases measured >5 cm (T3). Four (5.33%) cases belonged to T4 stage; all of them showing cutaneous infiltration. 10 (13.33%) patients had stage I disease, 45 (60%) had stage II disease and 20 (26.67%) had stage III disease. None had stage IV disease.

The assessment of stromal TILs was done as shown in (Table/Fig 1). The degree of stromal TIL infiltrate ranged from 10% to 95%, with a mean of 48.47% (standard deviation=24.203%). The patients were divided into nine groups based on the TIL infiltrate viz., 10-19%, 20-29%, 30-39%, 40-49%, 50-59%, 60-69%, 70-79%, 80-89% and 90-100%. Majority of the present cases 13 (17.33%) were in the TIL group 50-59%. The distribution of cases based on stromal TILs is given in (Table/Fig 2).

The scoring of peritumoural lymphocytes was done as shown in (Table/Fig 3). When studied for peritumoural lymphocytes, 25 (33.33%) cases had score 1 infiltrate, 34 (45.34%) had score 2 infiltrate and 16 (21.33%) had score 3 infiltrate. None had score 0 infiltrate. Low grade inflammation (scores 0 and 1) was seen in 25 (33.33%) cases and high grade inflammation (scores 2 and 3) in 50 (66.67%) cases.

The scoring of the lymphoid infiltrate on IHC is given in (Table/Fig 4). The distribution of cases based on the subpopulations of stromal TILs and peritumoural lymphocytes on IHC is given in (Table/Fig 5).

The association of stromal TILs and peritumoural lymphocytes with tumour grade, Lymphovascular Invasion (LVI) and axillary nodal metastasis is given in (Table/Fig 6). The lymphoid infiltrate in both compartments were significantly higher (p-value <0.05) in high grade IBC, NOS tumours. All cases of IBC with medullary features had high stromal TILs and high grade peritumoural infiltrate (95% and grade 3 in all 4 cases, respectively). There was no statistically significant association between stromal TILs/peritumoural lymphocytes and presence or absence of lymphovascular emboli (p-values of 0.454 and 0.324, respectively). The stromal TILs were significantly higher in cases without axillary node metastasis (p-value=0.049), while there was no statistically significant association between peritumoural lymphocyte infiltrate and presence or absence of axillary nodal metastasis (p-value=0.139).

Association between stromal TILs and peritumoural lymphocytes on H&E and CD4+ and CD8+ score in the corresponding compartment on IHC is given in (Table/Fig 7). The CD4+ and CD8+ scores were significantly higher in cases with high grade inflammation on H&E in both compartments.

Discussion

In the present study, patients with IBC were evaluated for the presence and degree of peritumoural infiltration and TILs and their association with tumour grade, lymphovascular emboli and axillary lymph node metastasis.

The majority of patients were in the age group of 50 to 59 years (36%). The age of the patients ranged from 30 years to 82 years, with a mean age of 52.31 years. This was comparable to studies by Chopra B et al., and Augustine P et al., the mean ages in their studies being 50.1 years and 47.79 years, respectively. The peak age groups in their studies were 41 to 50 years and 46 to 55 years, respectively (16),(17).

On histologic typing, 94.67% had IBC, NOS and the remaining 5.33% had IBC with medullary features. This was comparable to a study by Netra SM et al, where IBC with medullary features constituted 3.1% of the total cases (18). Of the 71 cases of IBC, NOS, 2.82% were grade 1, 83.10% were grade 2 and 14.08% were grade 3. Of the total 75 patients, lymphovascular emboli were noted in 22.67% of cases. Both these findings have shown variable results in other studies (10),(15),(19),(20), possibly related to the patient group visiting the specific institutions and the use of IHC in the detection of LVI (19).

Axillary lymph node evaluation showed that 44% patients had nodal metastasis. This was comparable to the study by Chakraborty A et al., where 44.36% patients showed metastasis (20). Of the 33 patients with axillary node metastasis, 51.52% had one to three positive nodes, 45.45% had four to nine positive nodes and the remaining 3.03% had 10 or more positive nodes. This was in concordance with a study by Mohapatra M and Satyanarayana S, where the positivity rates were 54.7%, 39.6% and 5.7%, respectively (21).

Categorisation based on tumour size showed that 18.67% patients had tumour size up to 2 cm (T1), 70.67% had tumour size >2 cm, but <5 cm (T2) and 5.33% had tumours >5 cm (T3). A 5.33% of patients showed skin infiltration (T4). The predominance of T2 tumours was identical to the study by Kaur M et al., with 70% of tumours in their study being in T2 stage (22).

Stage wise distribution of cases revealed that 13.33% patients presented with stage I disease, 60% with stage II disease and 26.67% with stage III disease. None had stage IV disease. This was comparable to the study by Mohapatra M and Satyanarayana S, where stage I disease was seen in 7.7% cases, stage II disease in 63.4% and stage III disease in 28.9%; none had stage IV disease in their study as well (21).

The degree of stromal TIL infiltrate ranged from 10% to 95%, with a mean of 48.47%. Majority of the present cases were in the TIL group 50-59% (17.33%), followed by 20-29% (14.67%). Low grade inflammation in the peritumoural area was seen in 33.33% cases and high grade inflammation in 66.67% cases.

The stromal TILs were significantly higher in high grade tumours. However, no significant association could be demonstrated between stromal TILs and lymphovascular emboli. Both these findings were similar to those in a study by Ruan M et al., who evaluated patients with triple negative breast cancer who had undergone neoadjuvant chemotherapy (23). A significantly higher TIL score was demonstrated in high grade triple negative breast cancers by Krishnamurti U et al., as well (24). A study by Lee HJ et al., also demonstrated that significantly higher TIL scores were associated with high grade tumours and reduced LVI (25).

The stromal TILs were found to be higher in cases without axillary lymph node metastasis. This was similar to a study by Caziuc A et al., who demonstrated reduced likelihood of nodal metastasis in both early stage as well as locally advanced tumours with higher TILs (26).

The present study showed that the peritumoural lymphocytic infiltrate was higher in high grade tumours. This finding was comparable to that in a study by Ahmadvand S et al., in which they demonstrated a significantly higher peritumoural infiltrate of CD3+, CD8+, CD45RO+ and FOXP3+ cells in high grade breast cancers (27). A similar result was obtained by Mohammed ZMA et al., in which high peritumoural lymphocytic infiltrate was significantly associated with higher tumour grade (28).

The present study failed to show a significant association between peritumoural lymphocytic infiltrate and lymphovascular emboli. This finding was similar to the study done by Al-Saleh K et al., where significant association was demonstrated only between pathological complete response and intratumoural CD8+TILs (10). The study by Ahmadvand S et al., and Mohammed ZMA et al., also could not demonstrate any association between peritumoural lymphocytic infiltrate and LVI (27),(28).

No significant association could be demonstrated between peritumoural lymphocytic infiltrate and axillary node metastasis. This was comparable to the study by Mohammed ZMA et al., where no significant association could be demonstrated between peritumoural lymphocytes and axillary nodal metastasis (28).

A significant association was obtained between the lymphocytes on H&E and the individual CD4+ and CD8+ cell infiltrate on IHC in both stromal and peritumoural compartments. A similar result was obtained by Konig L et al., with significant correlation between the total TILs on H&E and the CD3+, CD4+, CD8+ and CD20+ immune cell subpopulations in IHC (29).

Limitation(s)

The results of this study are dependent upon relatively small sample size. A similar study with a larger sample size might have increased the value of the study. Authors did not use any IHC markers for the detection of LVI, which might have improved the detection rate.

Conclusion

Stromal TILs and peritumoural lymphocytes were significantly higher in high grade tumours. Stromal TILs were also significantly higher in tumours without axillary lymph node metastasis. There is no statistically significant association between the lymphocytic infiltrate and LVI. There is significant association between H&E scoring of the immune infiltrate and immunohistochemical scoring of the subpopulations of the immune infiltrate.

Acknowledgement

We are extremely thankful to Dr Sathi PP, Professor and Head of Department, Department of Pathology for her help and support. We express our gratitude to Mrs. Usha, Mrs. Sreeja and Mr. Suneesh, technicians of the Histopathology lab, Govt. Medical College, Kozhikode for their help in doing IHC staining.

References

1.
Colditz G, Chia KS. Invasive Breast Carcinoma: Introduction and General Features. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds). WHO classification of tumours of the breast. 4th ed. Lyon: International Agency for Research on Cancer. 2012. Pp. 8-31.
2.
Collins LC. Breast. In: Goldblum JR, Lamps LW, McKenney JK, Myers JL (eds). Rosai and Ackerman's surgical pathology. 11th ed. Philadelphia: Elsevier, 2018. Pp. 1464-71, 1485-1503.
3.
Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017;13(4):289-95. [crossref] [PubMed]
4.
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-70. [crossref] [PubMed]
5.
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumour infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(11):259-71. [crossref] [PubMed]
6.
Iseki Y, Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, et al. A new method for evaluating tumour infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E) stained tumour sections. PLoS ONE. 2018;13(4):e0192744. [crossref] [PubMed]
7.
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-71. [crossref] [PubMed]
8.
Zitvogel L, Kepp O, Aymeric L, Ma Y, Locher C, Delahaye NF, et al. Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. Cancer Res. 2010;70(23):9538-43. [crossref] [PubMed]
9.
Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151-60. [crossref] [PubMed]
10.
Al-Saleh K, Abd El-Aziz N, Ali A, Abozeed W, Abd El-Warith A, Ibraheem A, et al. Predictive and prognostic significance of CD8(+) tumour-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. Oncol Lett. 2017;14(1):337-44. [crossref] [PubMed]
11.
Elston CW, Ellis IO. Pathological Prognostic Factors in Breast Cancer. I. The value of histologic grade in breast cancer: Experience from a large study with long term follow-up. Histopathology. 1991;19(1):403-10. [crossref] [PubMed]
12.
Amin MB, Edge SB, Greene F, Byrd DR, Brookland RK, Washington MK, Compton CC. eds. American Joint Committee on Cancer (AJCC) Staging Manual. 8th ed. New York: Springer, 2016.
13.
Brierley JD, Gospodarowicz MK, Wittekind C. eds. International Union against Cancer (UICC): TNM Classification of Malignant Tumours. 8th ed. Oxford: Wiley- Blackwell, 2016.
14.
Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005;41(17):2645-54. [crossref] [PubMed]
15.
Kreike B, Van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinoma. Breast Cancer Res. 2007;9(5):R65. Doi: 10.1186/bcr1771. [crossref] [PubMed]
16.
Chopra B, Kaur V, Singh K, Verma M, Singh S, Singh A. Age shift: Breast cancer is occurring in younger age groups- is it true? Clin Cancer Investig J. 2014;3(6):526-29. [crossref]
17.
Augustine P, Jose R, Peter A, Lal AA, Prabhakar J, Sreedharan J, et al. Risk factors of breast cancer in Kerala, India- a case control study. Academic Medical Journal of India. 2014;2(1):07-13.
18.
Netra SM, Vani BR, Murthy VS. Cytomorphological study of medullary carcinoma of breast in comparison to infiltrating ductal carcinoma. J Cytol. 2018;35(4):195-98.
19.
Agarwal S, Singh A, Bagga PK. Immunohistochemical evaluation of lymphovascular invasion in carcinoma breast with CD34 and D2-40 and its correlation with other prognostic markers. Indian J Pathol Microbiol. 2018;61(1):39-44. [crossref] [PubMed]
20.
Chakraborty A, Bose CK, Basak J, Sen AN, Mishra R, Mukhopadyay A. Determinants of lymph node status in women with breast cancer: A hospital based study from eastern India. Indian J Med Res. 2016;143(7):45-51. [crossref] [PubMed]
21.
Mohapatra M, Satyanarayana S. Evaluation of clinico-pathological findings of breast carcinoma in a general hospital in southern India. Indian J Cancer. 2013;50(4):297-301. [crossref] [PubMed]
22.
Kaur M, Kaur H, Manjari M, Rai V, Kaur K. Assessment of clinical parameters and histopathological grading of breast cancer. International Journal of Contemporary Medical Research. 2016;3(10):2938-41.
23.
Ruan M, Tian T, Rao J, Xu X, Yu B, Yang W, et al. Predictive value of tumour infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple negative breast cancers. Diagn Pathol. 2018;13(1):66. Doi: 10.1186/s13000-018-0743-7. [crossref] [PubMed]
24.
Krishnamurti U, Wetherilt CS, Yang J, Peng L, Li X. Tumour infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple negative but not estrogen receptor positive breast cancers. Hum Pathol. 2017;64:07-12. [crossref] [PubMed]
25.
Lee HJ, Kim JY, Park IA, Song IH, Yu JH, Ahn JH, et al. Prognostic significance of tumour infiltrating lymphocytes and the tertiary lymphoid structures in Her2 positive breast cancer treated with adjuvant trastuzumab. Am J Clin Pathol. 2015;144(2):278-88. [crossref] [PubMed]
26.
Caziuc A, Schlanger D, Amarinei G, Dindelegan GC. Can tumour infiltrating lymphocytes (TILs) be a predictive factor for lymph node status in both early stage and locally advanced breast cancer? J Clin Med. 2019;8(4):545. Doi: 10.3390/jcm8040545. [crossref] [PubMed]
27.
Ahmadvand S, Faghih Z, Montazer M, Safaei A, Mokhtari M, Jafari P, et al. Importance of CD45RO tumour infiltrating lymphocytes in postoperative survival of breast cancer patients. Cell Oncol. 2019;42(3):343-56. [crossref] [PubMed]
28.
Mohammed ZMA, Going JJ, Edwards J, Elsberger B, McMillan DC. The relationship between lymphocyte subsets and clinicopathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013;109(6):1676-84. [crossref] [PubMed]
28.
Konig L, Mairinger FD, Bankfalvi A. Dissimilar patterns of tumour infiltrating immune cells at the invasive tumour front and tumour center are associated with response to neoadjuvant chemotherapy in primary breast cancer. BMC Cancer. 2019;19(1):120. Doi: 10.1186/s12885-019-5320-2. [crossref] [PubMed]

DOI and Others

DOI: 10.7860/JCDR/2022/51545.15879

Date of Submission: Jul 24, 2021
Date of Peer Review: Sep 17, 2021
Date of Acceptance: Nov 20, 2021
Date of Publishing: Jan 01, 2022

AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. NA


PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Jul 27, 2021
• Manual Googling: Oct 01, 2021
• iThenticate Software: Nov 22, 2021 (9%)

ETYMOLOGY: Author Origin

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com